Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages
NCT ID: NCT01419392
Last Updated: 2012-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
80 participants
INTERVENTIONAL
2011-09-30
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Sildenafil Citrate on Mid Luteal Phase Uterine Artery Blood Flow in Patients With Recurrent Pregnancy Loss
NCT04718233
Sildenafil Citrate and Recurrent Abortion
NCT03475160
Sildenafil Citrate of in Vitro Fertilization After Multiple IVF Failures Attributed to Poor Endometrial Development
NCT03044561
Effect of Sildenafil Citrate on Uteri- Placental Perfusion, Doppler Indices in Growth Restricted Fetuses
NCT02362399
Sildenafil Effect After Ovulation Induction
NCT02890238
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sildenafil citrate
Sildenafil citrate
25 mg orally, 4 times per day for 21 days
placebo
matching placebo
orally, 4 times per day for 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sildenafil citrate
25 mg orally, 4 times per day for 21 days
matching placebo
orally, 4 times per day for 21 days
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Three or more recurrent miscarriages before the 24th week of gestation with no apparent cause for their previous losses
* Three or more months have elapsed since the last abortion
* Postmenstrual period
* No other therapy allowed during our treatment course
Exclusion Criteria
* Severe hepatic, renal, or cardiovascular impairment
* History of stroke or myocardial infarction
* Patients with retinitis pigmentosa.
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Tamer El-Refaie
Lecturer of Obstetrics and Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ain Shams University Maternity Hospital, Obstetrics and Gynecology Department
Cairo, Cairo Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ahmed-2004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.